Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | TNKS | O95271 | 4/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.35 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512872 | 0.85 | CYP19A1 (0.38) | — | |
| SCHEMBL512402 | 0.83 | WNT3A (0.46) | TNKS2WNT3APDE2A | |
| SCHEMBL1226818 | 0.82 | WNT3A (0.36) | TNKS2WNT3ATNKSPDE2AHTR2C | |
| SCHEMBL513059 | 0.81 | NR3C1 (0.42) | NR3C1 | |
| SCHEMBL15685511 | 0.81 | NR3C1 (0.33) | NR3C1 | |
| SCHEMBL512802 | 0.79 | TNKS2 (0.41) | TNKS2WNT3ATNKSPDE2APARP1 | |
| SCHEMBL512148 | 0.78 | CYP11B2 (0.34) | — | |
| SCHEMBL512723 | 0.78 | IDO1 (0.39) | HTR2C | |
| SCHEMBL16338862 | 0.78 | LMNA (0.34) | — | |
| SCHEMBL24355622 | 0.69 | HTR2C (0.46) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459197-A1 | COMPOUNDS FOR THE REDUCTION OF -AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | TNKS2 4000/4885WNT3A 1590/4885TNKS 4247/4885 |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | TNKS2 4000/4885WNT3A 1590/4885TNKS 4247/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | TNKS2 4000/4885WNT3A 1590/4885TNKS 4247/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | TNKS2 4000/4885WNT3A 1590/4885TNKS 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.